Back to results
US 10,896,749 B2Granted
Drug monitoring tool
AssigneeShire Human Genetic Therapies, Inc.
InventorsGerald Spotts, Roman Pichler, Michael Nelson
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure relate to a drug monitoring tool. The drug monitoring tool comprises a data receiver and an interactive user interface. The data receiver is configured to receive a pharmacokinetic (PK) profile of a patient. The interactive user interface is configured to display, to the patient, a time-varying therapeutic plasma protein level of the patient. The time-varying therapeutic plasma protein level is based on an administered dose of a clotting factor VIII and the PK profile of the patient.
Claims20
A drug monitoring tool, the tool comprising:
- a data receiver configured to receive, from a secured server, a patient pharmacokinetic (PK) profile of a patient, wherein the secured server comprises:
- (I) a Bayesian model of pharmacokinetic (PK) profiles of sampled patients, the Bayesian model including (i) a therapeutic plasma protein clearance and (ii) a volume of distribution relationship for a therapeutic plasma protein based upon at least one of patient age or body weight, and (II) a PK server configured to determine the patient PK profile based upon the Bayesian model, and at least one of a bodyweight, von Willebrand factor level, and an age of the patient;
- and
- an interactive user interface configured to:
- display to the patient a graphical representation predictive of a time-varying therapeutic plasma protein level of the patient, the time-varying therapeutic plasma protein level determined by the drug monitoring tool based on the timing and amount of an administered dose of a clotting factor VIII to the patient and the patient PK profile;
- and
- delineate a plurality of zones within the graphical representation associated with the time-varying therapeutic plasma protein level, the plurality of zones comprising at least:
- a safe zone indicating to the patient that the time-varying therapeutic plasma protein level is within a first concentration range considered safe for physical activity;
- and
- a danger zone indicating to the patient that the time-varying therapeutic plasma protein level is within a second concentration range and physical activity should be limited.
7 more elements
A drug monitoring system, the system comprising:
- a remote server system comprising:
- a Bayesian model of pharmacokinetic (PK) profiles of sampled patients, the Bayesian model including (i) a therapeutic plasma protein clearance and (ii) a volume of distribution relationship for a therapeutic plasma protein based upon at least one of patient age or body weight,
- a PK server that determines a patient PK profile based upon the Bayesian model and at least one of a bodyweight, von Willebrand factor level, and an age of a patient, and a quick response (QR) code generator that generates a QR code storing the patient PK profile;
- and
- a drug monitoring tool comprising:
- a camera that reads the QR code,
- a code processor that extracts the patient PK profile from the QR code, and
- an interactive user interface that displays a graphical representation of a time-varying therapeutic plasma protein level of the patient determined by the drug monitoring system based on the timing and amount of an administered dose of a clotting factor VIII to the patient and the patient PK profile, the graphical representation delineating a plurality of zones within the graphical representation associated with the time-varying therapeutic plasma protein level, the plurality of zones comprising at least:
- a safe zone indicating to the patient that the time-varying therapeutic plasma protein level is within a first concentration range considered safe for physical activity;
- and
- a danger zone indicating to the patient that the time-varying therapeutic plasma protein level is within a second concentration range and physical activity should be limited.
8 more elements
A method of using a patient pharmacokinetic (PK) profile to predict drug levels, the method comprising:
- receiving, at a user device, a patient PK profile for a clotting factor from a server system that determines the patient PK profile based on a Bayesian model of sampled patients and at least one of a bodyweight, a von Willebrand factor level, and an age of a patient;
- determining, by the user device, time-varying levels of the clotting factor predicted using the patient PK profile to result in the patient from the timing and amount of an administered dose of the clotting factor;
- and
- displaying, via an interactive user interface of the user device, the time-varying levels of the clotting factor predicted in the patient within a plurality of zones, the time-varying levels of the clotting factor being positioned within either:
- a safe zone indicating to the patient that the time-varying levels of the clotting factor is within a first concentration considered safe for physical activity;
- or
- a danger zone indicating to the patient that the time-varying levels of the clotting factor is within a second concentration and physical activity should be limited.
4 more elements
Dependencies are inferred from the claim text.